It is also important to note that PD-L1 can be expressed on immune cells, and it has been shown that quantifying PD-L1 on all cells in the tumour microenvironment, rather than just on the tumour cells, can better predict response to pembrolizumab [36]. The gene discussed is CD274; the disease is neoplasm.